{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T21:48:41Z","timestamp":1781560121679,"version":"3.54.5"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001778","name":"Deakin University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001778","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.ejim.2019.07.001","type":"journal-article","created":{"date-parts":[[2019,7,6]],"date-time":"2019-07-06T00:45:01Z","timestamp":1562373901000},"page":"70-76","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["The cost-effectiveness of omega-3 polyunsaturated fatty acids \u2013 The Australian healthcare perspective"],"prefix":"10.1016","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9734-1140","authenticated-orcid":false,"given":"Lan","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marj","family":"Moodie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Chuen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ejim.2019.07.001_bb0005","first-page":"E417-E","article-title":"Heart disease and stroke statistics-2015 update: A report from the American Heart Association (vol 131, pg e29, 2015)","volume":"133","author":"Mozaffarian","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2019.07.001_bb0010","author":"Australian Bureau of Statistics"},{"key":"10.1016\/j.ejim.2019.07.001_bb0015","author":"Australian Institute of Health and Welfare"},{"issue":"15","key":"10.1016\/j.ejim.2019.07.001_bb0020","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"issue":"10 Suppl","key":"10.1016\/j.ejim.2019.07.001_bb0025","doi-asserted-by":"crossref","first-page":"1K","DOI":"10.1016\/j.amjcard.2008.10.002","article-title":"The residual risk reduction initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia","volume":"102","author":"Fruchart","year":"2008","journal-title":"Am J Cardiol"},{"issue":"Suppl C","key":"10.1016\/j.ejim.2019.07.001_bb0030","doi-asserted-by":"crossref","first-page":"C2","DOI":"10.1093\/eurheartj\/suw009","article-title":"Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia","volume":"18","author":"Ferrari","year":"2016","journal-title":"Eur Heart J Suppl"},{"issue":"4","key":"10.1016\/j.ejim.2019.07.001_bb0035","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1161\/CIRCRESAHA.115.306249","article-title":"Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology","volume":"118","author":"Nordestgaard","year":"2016","journal-title":"Circ Res"},{"issue":"7","key":"10.1016\/j.ejim.2019.07.001_bb0040","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrcardio.2017.31","article-title":"Hypertriglyceridaemia and risk of coronary artery disease","volume":"14","author":"Reiner","year":"2017","journal-title":"Nat Rev Cardiol"},{"issue":"6","key":"10.1016\/j.ejim.2019.07.001_bb0045","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s11886-008-0079-0","article-title":"The role of triglycerides in cardiovascular risk","volume":"10","author":"Gandotra","year":"2008","journal-title":"Curr Cardiol Rep"},{"issue":"7","key":"10.1016\/j.ejim.2019.07.001_bb0055","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.amjcard.2012.05.031","article-title":"Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study)","volume":"110","author":"Ballantyne","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2019.07.001_bb0060","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.atherosclerosis.2016.08.018","volume":"253","author":"Catapano","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ejim.2019.07.001_bb0065","article-title":"AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"2018","author":"Grundy","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.ejim.2019.07.001_bb0070","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/eurheartj\/ehr112","article-title":"Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management","volume":"32","author":"Chapman","year":"2011","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.ejim.2019.07.001_bb0075","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1001\/jamacardio.2018.1306","article-title":"Questioning the associations of \u03c9-3 fatty acid supplement use with cardiovascular disease RisksQuestioning the associations of \u03c9-3 fatty acid supplement use with cardiovascular disease RisksLetters","volume":"3","author":"Cicero","year":"2018","journal-title":"JAMA Cardiol"},{"issue":"3","key":"10.1016\/j.ejim.2019.07.001_bb0080","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1517\/14656566.2015.991308","article-title":"Do we need \u2018new\u2019 omega-3 polyunsaturated fatty acids formulations?","volume":"16","author":"Cicero","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ejim.2019.07.001_bb0085","first-page":"485","article-title":"Icosapent ethyl for the treatment of severe hypertriglyceridemia","volume":"10","author":"Fares","year":"2014","journal-title":"Ther Clin Risk Manag"},{"issue":"1","key":"10.1016\/j.ejim.2019.07.001_bb0090","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with Icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.ejim.2019.07.001_bb0095","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1056\/NEJMc1902165","article-title":"Cardiovascular risk reduction with Icosapent ethyl","volume":"380","author":"Chan","year":"2019","journal-title":"N Engl J Med"},{"issue":"9567","key":"10.1016\/j.ejim.2019.07.001_bb0100","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","article-title":"Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis","volume":"369","author":"Yokoyama","year":"2007","journal-title":"Lancet."},{"issue":"360","key":"10.1016\/j.ejim.2019.07.001_bb0105","doi-asserted-by":"crossref","first-page":"854","DOI":"10.2307\/2286474","article-title":"Expressing the Kaplan-Meier estimator as a function of empirical subsurvival functions","volume":"72","author":"Peterson","year":"1977","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.ejim.2019.07.001_bb0110","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"issue":"8","key":"10.1016\/j.ejim.2019.07.001_bb0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v070.i08","article-title":"Flexsurv: a platform for parametric survival Modeling in R","volume":"70","author":"Jackson","year":"2016","journal-title":"J Stat Softw"},{"issue":"6","key":"10.1016\/j.ejim.2019.07.001_bb0120","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1177\/0272989X12472398","article-title":"Survival analysis for economic evaluations alongside clinical trials--extrapolation with patient-level data: inconsistencies, limitations, and a practical guide","volume":"33","author":"Latimer","year":"2013","journal-title":"Med Decis Mak"},{"issue":"15","key":"10.1016\/j.ejim.2019.07.001_bb0125","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1002\/sim.1203","article-title":"Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects","volume":"21","author":"Royston","year":"2002","journal-title":"Stat Med"},{"issue":"4","key":"10.1016\/j.ejim.2019.07.001_bb0130","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1177\/0272989X16670617","article-title":"Estimation of survival probabilities for use in cost-effectiveness analyses: a comparison of a multi-state modeling survival analysis approach with partitioned survival and Markov decision-analytic modeling","volume":"37","author":"Williams","year":"2017","journal-title":"Med Decis Mak"},{"key":"10.1016\/j.ejim.2019.07.001_bb0135","author":"Australian Bureau of Statistics"},{"key":"10.1016\/j.ejim.2019.07.001_bb0140","author":"Independent Hospital Pricing Authority"},{"key":"10.1016\/j.ejim.2019.07.001_bb0145","series-title":"National population and cost implications of treatment with Icosapentyl ethyl in the United States: An assessment based on the REDUCE-IT trial. bioRxiv","author":"Khera","year":"2018"},{"key":"10.1016\/j.ejim.2019.07.001_bb0150","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2458-12-398","article-title":"Improving the cost-effectiveness of cardiovascular disease prevention in Australia: a modelling study","volume":"12","author":"Cobiac","year":"2012","journal-title":"BMC Public Health"},{"issue":"8","key":"10.1016\/j.ejim.2019.07.001_bb0155","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.jval.2018.01.017","article-title":"Comparing the ICERs in medicine reimbursement submissions to NICE and PBAC\u2014does the presence of an explicit threshold affect the ICER proposed?","volume":"21","author":"Wang","year":"2018","journal-title":"Value Health"},{"key":"10.1016\/j.ejim.2019.07.001_bb0160","series-title":"Cardiovascular disease webpages data tables","author":"Australian Institute of Health and Welfare","year":"2018"},{"key":"10.1016\/j.ejim.2019.07.001_bb0165","author":"Australian Bureau of Statistics"},{"issue":"46","key":"10.1016\/j.ejim.2019.07.001_bb0170","doi-asserted-by":"crossref","DOI":"10.3310\/hta16460","article-title":"Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development","volume":"16","author":"Claxton","year":"2012","journal-title":"Health Technol Assess"},{"issue":"2","key":"10.1016\/j.ejim.2019.07.001_bb0175","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/hec.1161","article-title":"Expected value of information and decision making in HTA","volume":"16","author":"Eckermann","year":"2007","journal-title":"Health Econ"},{"key":"10.1016\/j.ejim.2019.07.001_bb0180","series-title":"Australian health survey: Biomedical results for chronic diseases, 2011-2012","author":"Australian Bureau of Statistics","year":"2013"},{"issue":"22","key":"10.1016\/j.ejim.2019.07.001_bb0185","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1093\/eurheartj\/ehs210","article-title":"Cost-effectiveness of optimizing prevention in patients with coronary heart disease: the EUROASPIRE III health economics project","volume":"33","author":"De Smedt","year":"2012","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.ejim.2019.07.001_bb0190","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s40273-016-0464-2","article-title":"A systematic review of cardiovascular outcomes-based cost-effectiveness analyses of lipid-lowering therapies","volume":"35","author":"Wei","year":"2017","journal-title":"Pharmacoeconomics."},{"issue":"5","key":"10.1016\/j.ejim.2019.07.001_bb0195","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1067\/mhj.2001.114805","article-title":"Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels","volume":"141","author":"Tsevat","year":"2001","journal-title":"Am Heart J"},{"key":"10.1016\/j.ejim.2019.07.001_bb0200","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.atherosclerosis.2016.08.005","article-title":"Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies","volume":"253","author":"Ballantyne","year":"2016","journal-title":"Atherosclerosis."},{"issue":"5","key":"10.1016\/j.ejim.2019.07.001_bb0205","first-page":"843","article-title":"Fish oil - how does it reduce plasma triglycerides?","volume":"1821","author":"Shearer","year":"2012","journal-title":"BBA-Mol Cell Biol L"},{"key":"10.1016\/j.ejim.2019.07.001_bb0210","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ijcard.2018.04.122","article-title":"The cost-effectiveness of PCSK9 inhibitors - the Australian healthcare perspective","volume":"267","author":"Kumar","year":"2018","journal-title":"Int J Cardiol"},{"issue":"2","key":"10.1016\/j.ejim.2019.07.001_bb0215","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/hec.1586","article-title":"Dangerous omissions: the consequences of ignoring decision uncertainty","volume":"20","author":"Griffin","year":"2011","journal-title":"Health Econ"},{"issue":"3","key":"10.1016\/j.ejim.2019.07.001_bb0220","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jval.2011.12.013","article-title":"Coverage with evidence development, only in research, risk sharing, or patient access scheme? A framework for coverage decisions","volume":"15","author":"Walker","year":"2012","journal-title":"Value Health"},{"issue":"12","key":"10.1016\/j.ejim.2019.07.001_bb0225","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/j.1753-4887.2010.00340.x","article-title":"Do specific dietary constituents and supplements affect mental energy? Review of the evidence","volume":"68","author":"Gorby","year":"2010","journal-title":"Nutr Rev"},{"issue":"5","key":"10.1016\/j.ejim.2019.07.001_bb0230","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/rheumatology\/ken024","article-title":"Cod liver oil (n-3 fatty acids) as an non-steroidal anti-inflammatory drug sparing agent in rheumatoid arthritis","volume":"47","author":"Galarraga","year":"2008","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.ejim.2019.07.001_bb0235","doi-asserted-by":"crossref","first-page":"784","DOI":"10.5114\/aoms.2012.31613","article-title":"Application of polyunsaturated fatty acids in internal medicine: beyond the established cardiovascular effects","volume":"8","author":"Cicero","year":"2012","journal-title":"Arch Med Sci"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095362051930216X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095362051930216X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:29:35Z","timestamp":1760606975000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095362051930216X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":46,"alternative-id":["S095362051930216X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2019.07.001","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The cost-effectiveness of omega-3 polyunsaturated fatty acids \u2013 The Australian healthcare perspective","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2019.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}